210 related articles for article (PubMed ID: 29458327)
1. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes.
Xi Y; Shi J; Li W; Tanaka K; Allton KL; Richardson D; Li J; Franco HL; Nagari A; Malladi VS; Coletta LD; Simper MS; Keyomarsi K; Shen J; Bedford MT; Shi X; Barton MC; Kraus WL; Li W; Dent SYR
BMC Genomics; 2018 Feb; 19(1):150. PubMed ID: 29458327
[TBL] [Abstract][Full Text] [Related]
2. A novel subtype classification and risk of breast cancer by histone modification profiling.
Chen X; Hu H; He L; Yu X; Liu X; Zhong R; Shu M
Breast Cancer Res Treat; 2016 Jun; 157(2):267-279. PubMed ID: 27178334
[TBL] [Abstract][Full Text] [Related]
3. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
[TBL] [Abstract][Full Text] [Related]
4. Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain.
Cai WL; Greer CB; Chen JF; Arnal-Estapé A; Cao J; Yan Q; Nguyen DX
BMC Med Genomics; 2020 Mar; 13(1):33. PubMed ID: 32143622
[TBL] [Abstract][Full Text] [Related]
5. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
[TBL] [Abstract][Full Text] [Related]
6. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
[TBL] [Abstract][Full Text] [Related]
7. Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes.
Messier TL; Gordon JA; Boyd JR; Tye CE; Browne G; Stein JL; Lian JB; Stein GS
Oncotarget; 2016 Feb; 7(5):5094-109. PubMed ID: 26783963
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression.
Santos GC; da Silva AP; Feldman L; Ventura GM; Vassetzky Y; de Moura Gallo CV
J Cell Biochem; 2015 Apr; 116(4):533-41. PubMed ID: 25358520
[TBL] [Abstract][Full Text] [Related]
9. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M
Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728
[TBL] [Abstract][Full Text] [Related]
10. Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60
Idrissou M; Lebert A; Boisnier T; Sanchez A; Houfaf Khoufaf FZ; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
OMICS; 2020 Oct; 24(10):581-591. PubMed ID: 32960142
[TBL] [Abstract][Full Text] [Related]
11. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract][Full Text] [Related]
12. SILAC-based proteomic analysis to dissect the "histone modification signature" of human breast cancer cells.
Cuomo A; Moretti S; Minucci S; Bonaldi T
Amino Acids; 2011 Jul; 41(2):387-99. PubMed ID: 20617350
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Hitchler MJ; Oberley LW; Domann FE
Free Radic Biol Med; 2008 Dec; 45(11):1573-80. PubMed ID: 18845242
[TBL] [Abstract][Full Text] [Related]
14. Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypes.
Xu J; Wang Z; Li S; Chen J; Zhang J; Jiang C; Zhao Z; Li J; Li Y; Li X
Brief Bioinform; 2018 Jan; 19(1):52-64. PubMed ID: 27742663
[TBL] [Abstract][Full Text] [Related]
15. Epigenomic analysis in a cell-based model reveals the roles of H3K9me3 in breast cancer transformation.
Li QL; Lei PJ; Zhao QY; Li L; Wei G; Wu M
Epigenomics; 2017 Aug; 9(8):1077-1092. PubMed ID: 28762778
[TBL] [Abstract][Full Text] [Related]
16. Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis.
Kikutake C; Yahara K
PLoS One; 2016; 11(4):e0152918. PubMed ID: 27042856
[TBL] [Abstract][Full Text] [Related]
17. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
Wilson S; Fan L; Sahgal N; Qi J; Filipp FV
Oncotarget; 2017 May; 8(18):30328-30343. PubMed ID: 28416760
[TBL] [Abstract][Full Text] [Related]
18. Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancer.
Fritz AJ; Ghule PN; Boyd JR; Tye CE; Page NA; Hong D; Shirley DJ; Weinheimer AS; Barutcu AR; Gerrard DL; Frietze S; van Wijnen AJ; Zaidi SK; Imbalzano AN; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2018 Feb; 233(2):1278-1290. PubMed ID: 28504305
[TBL] [Abstract][Full Text] [Related]
19. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
[TBL] [Abstract][Full Text] [Related]
20. Functional elements demarcated by histone modifications in breast cancer cells.
Choe MK; Hong CP; Park J; Seo SH; Roh TY
Biochem Biophys Res Commun; 2012 Feb; 418(3):475-82. PubMed ID: 22285863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
